<DOC>
	<DOCNO>NCT00080002</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy pegamotecan ( PEG-camptothecin ) patient pathologically-diagnosed locally advanced metastatic adenocarcinoma stomach gastroesophageal junction relapse progress follow one prior chemotherapy treatment regimen .</brief_summary>
	<brief_title>Efficacy Pegamotecan ( PEG-Camptothecin ) Localized Metastatic Cancer Stomach Gastroesophageal Junction</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Pathologically confirm diagnosis adenocarcinoma stomach gastroesophageal junction . Disease measurable least one dimension . Target tumor outside prior radiation field ( ) . An Eastern Cooperative Oncology Group ( ECOG ) performance scale score 0 1 Adequate hematologic profile , determine hemoglobin , platelet , neutrophil count . Adequate renal function , determine serum creatinine serum albumin measurement . Adequate liver function , determine total bilirubin transaminase level . Transaminases may &lt; = 5.0x ULN due metastatic disease liver . Fully recover prior surgery . No history hemorrhagic cystitis . No microscopic hematuria ( &gt; 10 RBC/hpf ) unless document due infection nonbladder origin . Capable understand protocol requirement risk provide write informed consent . Concurrent serious medical illness unrelated tumor within past 6 month . Known chronic infectious disease , AIDS hepatitis ( screen hepatitis HIV perform ) . Positive screening pregnancy test breastfeeding . Female male subject reproductive capacity unwilling use method appropriate prevent pregnancy course study . Receiving concurrent chemotherapy , investigational agent , radiotherapy , surgery , receive wide field radiation within previous 4 week . History another malignancy ( except basal squamous cell carcinoma skin carcinoma situ cervix ) within last 5 year . Known clinically suspect brain metastasis . Received one prior regimen chemotherapy locally advanced metastatic adenocarcinoma stomach GE junction . Received prior neoadjuvant and/or adjuvant cytotoxic chemotherapy Received investigational drug within last 30 day . Not fully recover prior , reversible side effect relate administration cytotoxic chemotherapy , investigational agent , radiation therapy . Prior treatment camptothecin analog .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>cancer</keyword>
	<keyword>gastric</keyword>
	<keyword>gastroesophageal junction</keyword>
	<keyword>neoplasm</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>gastric neoplasm</keyword>
</DOC>